Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accomplish, accomplished, accomplishing, acquiescence, adjudicated, anniversary, annum, ARB, Arizona, asminority, assetimpairmentsincluded, assetsand, attachment, availablecash, Bainbridge, bankrupt, barred, Bayer, Bexxar, bid, binder, binding, Biogen, Biopharma, biosimilar, bisplatinate, BLA, bonded, branch, brostallicin, carryover, chain, CHMP, CIA, CMO, Commissione, compelling, contacted, convenience, covenant, creation, CSP, custodian, custody, Debtor, decide, decided, defray, delisted, depository, deprive, diagnostic, diffuse, discrepancy, diversion, DNA, dossier, doublet, entry, EORTC, explanatory, expressly, extraordinary, Favrille, feel, fill, FIT, flat, follicular, foreclosure, formation, Frederick, GE, Genetic, Genitope, Genmab, Genta, GlaxoSmithKline, grace, groove, heavily, hematopoietic, highest, Histological, HITT, hundred, Ibritumomab, Idec, indemnification, indemnify, inInternal, inpreferred, insolvency, insolvent, Inspector, instance, instruction, involuntary, isotope, justification, landscape, le, leveraged, liposarcoma, LLC, LP, Malinckrodt, mark, Medicaid, merged, mezzanine, MTA, multiplied, municipal, myxoid, Nazionale, nineteen, noncontrolling, Nordion, outpatient, owner, paragraph, partnership, pattern, petition, PharmaMar, PHSA, physical, platform, positron, possession, potency, preceding, promissory, put, qualitative, quickly, quotient, radioimmunotherapeutic, radioimmunotherapy, radioisotope, radiopharmaceutical, ratification, reaction, rebrand, recurring, relief, rendered, resolution, retitled, retroactively, risky, sample, sarcoma, sBLA, scan, Schering, Scottsdale, script, Secondaria, SEER, seizure, SM, Societ, soft, sophisticated, Southern, speed, stabilize, stayed, stronger, sublicense, succeeding, switching, symptom, synergy, synthetic, Tang, TGen, thousand, throughput, Titoli, Tiuxetan, tomography, Topic, travel, trustee, Tucson, unamortized, uncollectible, uncontested, undeveloped, unfamiliar, unique, unreserved, untreated, user, warranty, wider, writ, Zevalin
Removed:
accrual, aggressively, answered, antibody, ASCO, asserting, auditing, aware, bladder, body, bore, BSHAP, cisplatin, conceived, confirmed, construed, cytarabine, damaged, dexamethasone, diarrhea, disclose, discovered, discovering, ejection, enabling, encouraging, ESHAP, esophageal, etoposide, extended, fluctuation, forming, fraction, furnish, GAAP, gastric, gastrointestinal, hematologic, Hematologica, hematuria, Hoffman, infrequent, infusional, invalid, journal, lacked, largely, left, LIBOR, Link, LLP, loan, marker, marketable, Max, metastatic, methylprednisolone, Mexico, modifying, Munich, netted, optimization, optionee, PanGenex, patented, periodic, Phil, purportedly, recurrent, relation, requiring, retaining, Roche, sought, spread, subjected, successor, systemic, targeting, thereunder, thornton, threshold, tolerated, typical, underwriter, unlawful, variant, variation, ventricular, Vermont
Filing tables
Filing exhibits
- 10-K Annual report
- 12.1 Statement Re: Computation of Ratio of Earnings to Fixed Charges
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32 Certification of Chief Executive Officer and Chief Financial Officer
Related press release
CTIC similar filings
Filing view
External links
Exhibit 12.1
STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(in thousands)
Year Ended December 31, | |||||||||||||||
2007 | 2006 | 2005 | 2004 | 2003 | |||||||||||
Net loss attributable to common shareholders | (148,305 | ) | (135,819 | ) | (102,505 | ) | (252,298 | ) | (130,031 | ) | |||||
Add: fixed charges | 15,421 | 45,147 | 18,942 | 12,504 | 10,694 | ||||||||||
Earnings as defined | (132,884 | ) | (90,672 | ) | (83,563 | ) | (239,794 | ) | (119,337 | ) | |||||
Fixed charges: | |||||||||||||||
Interest expensed and capitalized | 14,827 | 44,582 | 17,559 | 10,988 | 9,326 | ||||||||||
Estimated interest component of rent | 594 | 565 | 1,383 | 1,516 | 1,368 | ||||||||||
Total fixed charges | 15,421 | 45,147 | 18,942 | 12,504 | 10,694 | ||||||||||
Ratio of earnings to fixed charges | (1 | ) | (1 | ) | (1 | ) | (1 | ) | (1 | ) |
(1) | Earnings (as defined) for the period were insufficient to cover fixed charges by an amount equal to the net loss attributable to common shareholders for the period. |